MedTrace Logo

HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC

NCT02038335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 451

Last updated 2020-12-03

No results posted yet for this study

Summary

This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections that have started. Immune cells are also the type of cells that HIV (human immunodeficiency virus) infects so understanding more about them will help to better understand how to prevent the spread of HIV.

Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: Depo-Provera (DMPA), NET-EN, MPA/E2 (Cyclofem®), the levonorgestrel subdermal implant (Jadelle® ), the etonogestrel subdermal implant (Implanon® or Nexplanon® ) and the copper IUD.

Conditions

  • Contraception
  • HIV
  • Immune Cells (Mucosal and Systemic)
  • Microbiota

Interventions

DRUG

DMPA

Depot medroxyprogesterone acetate

DRUG

NET-EN

Norethisterone enantate

DRUG

MPA/E2

Medroxyprogesterone acetate and estradiol cypionate

DEVICE

LNG-I

Levonorgestrel subdermal implant

DEVICE

ENG-I

Etonogestrel subdermal implant

DEVICE

Cu-IUD

Copper IUD

Sponsors & Collaborators

  • University of Zimbabwe

    collaborator OTHER

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Sharon Achilles, MD, PhD · University of Pittsburgh

  • Felix Mhlanga, MD · University of Zimbabwe, University of California San Francisco

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-06-30
Completion
2020-12-31

Countries

  • Zimbabwe

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038335 on ClinicalTrials.gov